Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
348 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Currently Recruiting (2)
  • Closed (1)

Medical Condition

  • Show all (105)
  • Autoimmune Disorders (1)
  • Blood Disorders (1)
  • Cancer (89)
    • Brain Cancer (1)
    • Leukemia (8)
    • (-) Lung Cancer (2)
    • Lymphoma (45)
    • Multiple Myeloma (1)
    • Solid Tumors (2)
  • (-) Neurological Disorders (1)
    • Brain Tumors (1)
  • Pediatrics (12)
  • Transplant (1)
Displaying 1 - 3 of 3

Study of Tirabrutinib in Patients with Primary Central Nervous System Lymphoma (PCNSL)

Condition: Neurological Disorders / Brain Tumors
Investigator: Fabio Iwamoto, MD
Status: Currently Recruiting
The purpose of this study is to learn the effects of the investigational new drug, tirabrutinib, when given for the treatment of PCNSL. Investigational new drug means a drug that has not been approved as a marketed product (that is, available to be prescribed or sold) by the United States (US) Food and Drug Administration (FDA). Tirabrutinib acts by…
Read More

Study of Durvalumab in Patients with Non-Small Cell Lung Cancer (NSCLC)

Condition: Cancer / Lung Cancer
Investigator: Benjamin Herzberg, MD
Status: Currently Recruiting
The purpose this study to learn more about if a medication called durvalumab will work and be safe for the treatment of non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic) with certain genetic changes when given in combination with tremelimumab and standard chemotherapy. Additionally, this study is being done to better…
Read More

A study for patients with advanced non-small cell lung cancer using study drug Alectinib

Condition: Cancer / Lung Cancer
Investigator: Sewanti Limaye, MD
Status: Closed
The purpose of this study is to compare the effects, good or bad, of drugs alectinib and crizotnib on patients with lung disease to find out which is better for patients with a special type of non-small cell lung cancer (NSCLC) that is called anaplastic lymphoma kinase (ALK)-positive NSCLC. In this study, participants will…
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science